tbuckley/cabot-search huggingface dataset:
The quest for ingested peanut protein in human serum
Authors: Anja Pahlow Mose, Ejvind Mortz, Per Stahl Skov, Charlotte Gotthard Mortz, Esben Eller, Ulrik Sprogøe, Torben Barington, Carsten Bindslev‐Jensen
Journal: Allergy (2019)

Abstract Background There is mounting evidence that systemic uptake of food allergens is key to triggering anaphylaxis. However, direct proof for this theory is still lacking. The purpose of this study was to quantify the absorption and to determine the absorption kinetics of immunoreactive peanut protein in relation to the allergic response in human. Methods Quantitative protein assays including mass spectrometry, dot blots and Western blotting were developed to determine the level of Ara h 2 absorption in human serum. The double monoclonal sandwich ELISA was applied to quantify absorbed Ara h 2 and 6, and the basophil histamine release assay and the human passive cutaneous anaphylaxis test were utilized to study the absorption kinetics of immunologically intact peanut proteins. Results The protein assays worked but were not sensitive enough to trace the minute amounts of absorbed Ara h 2 in human serum. The level of Ara h 6 in serum was found to be up to 0.2 ng/mL, but Ara h 2 could not be detected with the ELISA. Both the in vivo and the in vitro methods were successful in demonstrating that: immunoreactive peanut protein was absorbed shortly after ingestion (≤5 minutes); the peanut protein concentration peaks between 1 and 4 hours; and peanut proteins can circulate for at least 48 hours in the bloodstream. Conclusion Ingested peanut protein is absorbed systemically and retains its immunoreactive capacity in human serum. However, the precise quantities and the implication for the elicitation of anaphylaxis remains to be elucidated.
Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting
Authors: Tatyana Ionova, Boris Afanasiev, Maria Andrievskih, Alim Amdiev, Elena A. Baryakh, Viktor Chang, Gulnara Husainova, Vladimir Ivanov, Kamil D Kaplanov, Oksana Kaverina, Tatiana Klitochenko, Vyacheslav Kurakin, Olga Larionova, Darya Lazareva, Kirill Lepik, Irina Lysenko, Nataliia Mikhailova, Raisa Minullina, Oleg Mironov, Elena Misyurina, Nikita Mochkin, Tatiana Nikitina, Iurii Osipov, Tatiana Petrova, Natalia Porfirieva, Oleg Rykavitcin, Rustem Safin, Tatiana Shelekhova, Dmitrij Sherstnev, Polina Simashova, Elena Smirnova, Natalia Trenina, Evgeniy V. Vasiliev, Mikhail Volkov, Elena Volodicheva
Journal: Blood (2019)
An IDO1-Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia
Authors: Simone Ragaini, Sarah Wagner, Giovanni Marconi, Sarah Parisi, Chiara Sartor, Jacopo Nanni, Gianluca Cristiano, Annalisa Talami, Matteo Olivi, Darina Ocadlikova, Marilena Ciciarello, Giulia Corradi, Emanuela Ottaviani, Cristina Papayannidis, Stefania Paolini, Jayakumar Vadakekolathu, Michele Cavo, Sergio Rutella, Antonio Curti
Journal: Blood (2019)
Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Authors: Rodney H Falk, Morie A Gertz, Merrill D Benson, Gustavo Buchele, Michela Brambatti, Sotirios Tsimikas, Nicholas J Viney, Li-Jung Tai, Cecilia Monteiro, Qingqing Yang, Louis St L O'Dea, Ewa Karwatowska-Prokopczuk, Eugene Schneider, Richard S Geary, Brett P Monia
Journal: Blood (2019)
The BET Protein BRD2 Cooperates with CTCF to Enforce a Transcriptional Boundary in Erythroid Cells
Authors: Sarah C. Hsu, Caroline Bartman, Aaron J Stonestrom, Christopher R Edwards, Thomas Gilgenast, Daniel Emerson, Peng Huang, Michael T. Werner, Kristen Jahn, Cheryl A. Keller, Belinda Giardine, Ross C. Hardison, Arjun Raj, Jennifer E. Phillips-Cremins, Gerd A. Blobel
Journal: Blood (2016)
Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)
Authors: Binod Dhakal, Muhammad Umair Mushtaq, Ashley Cunningham, Athanasios Papadas, Adam Pagenkopf, Joshua Wiesner, Catherine Leith, Peiman Hematti, Parameswaran Hari, Natalie Scott Callander, Fotis Asimakopoulos
Journal: Blood (2019)
Urinary Infection in Childhood
Authors: K. Harden
Journal: BMJ (1964)

Rule of Three" SIR,-Some official rebuke from the B.M.A. should surely be made to the Minister of Transport in his recommendation that three drinks should be taken before driving at Christmas.His "rule of three" must surely be the most imprudent advice given to motorists for many a decade.The rule of "none for the road" should always apply.-I am, etc., lo0n1(101 W.1. Guy
Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
Authors: Margaret V. Ragni, Craig D. Seaman, Diana Gilligan, Claire S. Philipp, Anne T. Neff, Robert F. Sidonio, Philip Kuriakose, Tzu-Fei Wang, Lynn M. Malec, Rajiv K. Pruthi, Elaine Majerus, George M. Rodgers, Danielle Nance, Nina Hwang, Barbara A. Konkle, Andrew D. Leavitt, Joseph Lasky, Allison P. Wheeler, Roshni Kulkarni, Tammuella Singleton, Dana Ivanco, Elynna Youm, Glory Koerbel, Scott Rothenberger, Doris M. Rubio
Journal: Blood (2019)
Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders
Authors: Peter Stewart, Jana Gazdova, Nikos Darzentas, Dorte Wren, Paula Proszek, Grazia Fazio, Simona Songia, Miguel Alcoceba, Maria Eugenia Sarasquete, Patrick Villarese, Michèle Y van der Klift, Kim Heezen, Neil McCafferty, Karol Pal, Mark Catherwood, Chang Sik Kim, Shambhavi Srivastava, Elizabeth Hodges, Kostas Stamatopoulos, Wolfram Klapper, Simone Ferrero, Michiel van den Brand, Giovanni Cazzaniga, Frederic Davi, Ramon Garcia-Sanz, Patricia Groenen, Elizabeth Macintyre, Monika Brüggemann, Christiane Pott, Elisa Genuardi, Anton W Langerak, David Gonzalez
Journal: Blood (2019)
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
Authors: Mazyar Shadman, Jordan Gauthier, Sirin Khajavian, Alexandre V. Hirayama, Ryan C. Lynch, Stephen D. Smith, Chaitra S. Ujjani, Victor A. Chow, Hans-Peter Kiem, Brian G. Till, Ajay K. Gopal, David G. Maloney, Cameron J. Turtle
Journal: Blood (2019)
Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant
Authors: Sayeef Mirza, Ankita Tandon, Dakota Jenneman, Shu Cao, Ambuj Kumar, Michelle R. Kidd, Farhad Khimani, Asmita Mishra, Hien D. Liu, Taiga Nishihori, Lia Perez, Nelli Bejanyan, Joseph Pidala, Michael Nieder, Hany Elmariah
Journal: Blood (2019)
CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia
Authors: Tiffany A. Hylkema, Laura Pardo, Keith R. Loeb, Quy Le, Suzan Imren, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi
Journal: Blood (2019)
Ian Michael Lowit
Authors: Michael Maas-Lowit
Journal: BMJ (2019)

Ian Michael Lowit, who died peacefully two months after his 100th birthday, had a remarkable life. Born Hans Lowit in Vienna in 1919, he enrolled in the Faculty of Medicine in the University of Vienna in the winter semester of 1937-38, during which he met Sigmund Freud. His mother was an acquaintance of psychotherapist Alfred Adler, and his early exposure to the atmosphere of psychotherapy in Viennese culture undoubtedly influenced Ian’s later career choices. However, being Jewish, Ian was expelled, and he and his mother were forced to …
Partial Gastrectomy for Peptic Ulcer
Authors: J. Morley, F. H. Bentley
Journal: BMJ (1938)

Depressed in all cases.Free bile regurgitation occurred in all.No frce acid detected in any case.Average emptying time, three- quarters of an hour.Blood Picture:Normal count: 3 cases-2 ma!e, I female.Microcytic anaemia: 5 cases-2 male, 3 female.Haemoglobin percentages, 82 'a treated anaemia, was previously 40), 80, 63, 54, 38.Macrocytic anaemia : 1 case-a female.Operation, 1925. 1928,microcytic anaemia (Jib 48%; colour index 0.48).1935, macrocysic anaemia (Hb 38%; colour index 1.32).General Health:Good: 6 cases (Criteria of " good health ": no illnesses, no com- plaints, working).Good until pernicious anaemia developed, now good again under treatment: I case.Fair: 2 cases.Both have microcytic anaemia with complaints of the anaemia.Ulcer Symptoms Since Operation.-Nocase.SCHOEMAKER GASTRECTOMY.-58cases: 43 mnale, 15 fem1ale.Number of years since operation : ntaximumn 14, mnitnimumn 4, average 8.In 45 cases gastric function was depressed (Group 1).iln 13 cases gastric fuinction was active (Group 2) GROUP I CASES: 45 cases-31 male, 14 female Gastric Function:Depressed in all cases.Bile regurgitation present.Free acid : in 34 cases no free acid detected; in 11 cases free acid was between 1 and 20 c.cm. N/10 acid.Average emptying time, 1 hour.In 27 of these cases gastric function was greatly depressed (comparable with the Polya cases).Blood Picture:
Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR aGVHD) Pediatric Patients
Authors: Tracy Westley, Dimitrios Tomaras, Eric Strati, Donna Skerrett, Anna Forsythe, Gabriel Tremblay
Journal: Blood (2019)
Testicular Metastasis of Pancreatic Carcinoma on FDG-PET/CT
Authors: Guozhu Hou, Yuanyuan Jiang, Xin Cheng
Journal: Clinical Nuclear Medicine (2019)

Pancreatic cancer metastasizing to the testis is extremely rare. We present the case of a 65-year-old man who complained of painless swelling of the left scrotum for 9 months. Scrotal ultrasonography revealed a mass in the left testis. Serum CA199 and CA242 were significantly elevated. F-FDG PET/CT was recommended for identifying potential malignancy and showed several hypermetabolic masses in the pancreas, left testis, and right lung. Resection of left testicular and pancreatic masses and fine-needle biopsy of right pulmonary mass were performed, and subsequent pathology confirmed pancreatic adenocarcinoma metastasizing to the testis and lung.
Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia
Authors: Montreh Tavakkoli, Justin D. Kaner, Sharma Sahil, Tony Taldone, Swathi Merugu, Gabriela Chiosis, Gail J. Roboz, Monica L. Guzman
Journal: Blood (2019)
Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression
Authors: Anees M. Dauki, James S. Blachly, Esko A. Kautto, Sameera Ezzat, Mohamed H. Abdel-Rahman, Christopher C. Coss
Journal: Cancer Research (2019)

Abstract Owing to the marked sexual dimorphism of hepatocellular carcinoma (HCC), sex hormone receptor signaling has been implicated in numerous aspects of liver cancer pathogenesis. We sought to reconcile the clear contribution of androgen receptor (AR) activity that has been established in preclinical models of HCC with the clinical failure of AR antagonists in patients with advanced HCC by evaluating potential resistance mechanisms to AR-targeted therapy. The AR locus was interrogated for resistance-causing genomic modifications using publicly available primary HCC datasets (1,019 samples). Analysis of HCC tumor and cell line RNA-seq data revealed enriched expression of constitutively active, treatment-refractory AR splice variants (AR-SV). HCC cell lines expressed C-terminal–truncated AR-SV; 28 primary HCC samples abundantly expressed AR-SV. Low molecular weight AR species were nuclear localized and constitutively active. Furthermore, AR/AR-SV signaling promoted AR-mediated HCC cell progression and conferred resistance to AR antagonists. Ligand-dependent and -independent AR signaling mediated HCC epithelial-to-mesenchymal transition by regulating the transcription factor SLUG. These data suggest that AR-SV expression in HCC drives HCC progression and resistance to traditional AR antagonists. Novel therapeutic approaches that successfully target AR-SVs may be therapeutically beneficial for HCC. Significance: Treatment-refractory, constitutively active androgen receptor splice variants promote hepatocellular carcinoma progression by regulating the epithelial-to-mesenchymal transition pathway.
Spectrum of Neurologic Complications after Allogeneic Hematopoietic Cell Transplantation for Hematologic Diseases in Adults: Systematic Review and Meta-Analysis
Authors: Maria Gavriilaki, Maria Mainou, Eleni Gavriilaki, Anna-Bettina Haidich, Sotirios Papagiannopoulos, Ioanna Sakellari, Achilles Anagnostopoulos, Vasilis Kimiskidis
Journal: Blood (2019)
Author Correction: Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs
Authors: Mohammed F. Shaheen, Dong Jin Joo, Jeffrey J. Ross, Brett D. Anderson, Harvey S. Chen, Robert C. Huebert, Yi Li, Bruce Amiot, Anne Young, Viviana Zlochiver, Erek Nelson, Taofic Mounajjed, Allan B. Dietz, Gregory Michalak, Benjamin G. Steiner, Dominique Seetapun Davidow, Christopher R. Paradise, Andre J. van Wijnen, Vijay H. Shah, Mengfei Liu, Scott L. Nyberg
Journal: Nature Biomedical Engineering (2019)
Donor-Derived Ex-Vivo Activated NK Cells in Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Acute Leukemia
Authors: Xing-Yu Cao, Tong Wu, Bi-Ping Deng, Rui-Juan Sun, Yue Lu, Yan-Li Zhao, Jian-Ping Zhang, Jia-Rui Zhou, Zhi-Jie Wei, Xiu-Yan Tao, Hui Wang, Hong-Xing Liu, Dao-Pei Lu, Chun-Rong Tong
Journal: Blood (2014)
Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial
Authors: Fernanda S Seguro, Felipe VR Maciel, Guilherme O Lopes, Luciana Nardinelli, Vanderson Rocha, Israel Bendit
Journal: Blood (2019)
The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Authors: Koji Sasaki, Hagop M. Kantarjian, Elias Jabbour, Farhad Ravandi, Marina Y Konopleva, Gautam M. Borthakur, William G. Wierda, Naval G. Daver, Koichi Takahashi, Kiran Naqvi, Courtney D. DiNardo, Guillermo Montalban Bravo, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Ghayas C. Issa, Preetesh Jain, Jeffrey Skinner, Mary B. Rios, Sherry A. Pierce, Kelly Soltysiak, Junya Sato, Guillermo Garcia-Manero, Jorge E. Cortes
Journal: Blood (2019)
A Distinct Subgroup of Diffuse Large B Cell Lymphoma with Poor Prognosis, Bcl-2 Superexpressor
Authors: Jin Roh, Hyungwoo Cho, Hyo-Kyung Pak, Ah Ra Jung, Yoon Sei Lee, Sang-wook Lee, Jin-Sook Ryu, Eun Jin Chae, Kyoung Won Kim, Jooryung Huh, Cheolwon Suh, Dok Hyun Yoon, Chan-Sik Park
Journal: Blood (2019)
Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study
Authors: Nicolas Boissel, Josep-Maria Ribera, Sabina Chiaretti, Alessandro Rambaldi, Renato Bassan, Cristina Papayannidis, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Robin Foà
Journal: Blood (2019)
RARE-28. HYPOTHALAMIC GERMINOMA AND NEUROSARCOIDOSIS: A TALE OF TWO PATHOLOGIES
Authors: Sushant Puri, Tibor Valy-Nagy, Nadera Sweiss, Stefania Maraka, Martin Nicholas
Journal: Neuro-Oncology (2019)

Abstract CASE 1: 30-year-old Caucasian male with a history of hereditary cavernomas, testicular germ cell tumor s/p orchiectomy 2017 presented next year with a chief complain of increasing lethargy. MRI Brain showed a new expansile, homogenously enhancing hypothalamic lesion causing obstructive dilatation of the lateral ventricles. MRI of neuraxis was not concerning for leptomeningeal spread. Initial differentials included suprasellar germinoma vs chiasmatic hypothalamic glioma vs metastatic lesion. Biopsies X2 showed gliosis and granulomatous inflammation. Despite radiation treatment for the hypothalamic mass clinical course continued to deteriorate. CSF results showed RBC - 1,200; WBC - 51 with 77% lymphocytes, 3% neutrophils, 20% monocytes. FDG-PET did not reveal evidence of metastatic disease. He was treated presumptively for neurosarcoidosis with high-dose corticosteroids and azathioprine and later transitioned to methotrexate and infliximab. Follow up MRI scans showed a reduction in the hypothalamic mass. CASE 2: A 23-year-old African American male treated for ADEM in 2010 presented to clinic with behavioral problems in 2017. Initial presentation included lethargy with imaging showing an incidental hypothalamic mass. Initial differentials included germinoma vs infundibular hypophysitis vs granulomatous process. He was treated with immunotherapy (corticosteroids and IVIG) with partial resolution of the growth. He was later diagnosed with suprasellar germinoma on biopsy subsequently treated with 2 cycles chemotherapy and proton beam radiotherapy in 2012. In 2017. to exclude tumor recurrence an LP showed elevated ACE however remainder of the clinical picture was not suggestive of neurosarcoidosis. DISCUSSION: Multiple case series have been described wherein hypothalamic germinoma mimics isolated neurosarcoidosis and vice-versa. Because of similar clinical picture and radiographic findings, the diagnosis is challenging. ACE is a nonspecific test for neurosarcoidosis, and it can be positive in the setting of germinoma as well. Hence specific molecular markers may be helpful in the diagnosis.
Prevalence and Predictors of Non-Adherence to 6-Mercaptopurine (6MP) in Children with Acute Lymphoblastic Leukemia (ALL) - a Children’s Oncology Group Study.
Authors: Smita Bhatia, Doojduen Villaluna, Wendy Landier, Alexandra Schaible, Lindsey Hageman, Cara Hanby, Wendy Leisenring, Stephen P. Hunger, Leslie L. Robison, Mary V. Relling, F. Lennie Wong
Journal: Blood (2008)
Pragmatic Trials and Repurposed Drugs for Alzheimer Disease
Authors: Lon S. Schneider
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
TMIC-15. HYPERACTIVATING THE HIPPO PATHWAY EFFECTOR TAZ DIFFERENTIALLY DISTORTS THE TUMOR MICROENVIRONMENT, PROMOTES TUMOR-ASSOCIATED NEUTROPHIL INFILTRATION, AND PHENOCOPIES MESENCHYMAL-GLIOBLASTOMA
Authors: Patricia Yee, Yiju Wei, Zhijun Liu, Hui Guo, Umeshkumar Manjibhai Vekariya, Benjamin Anderson, Wei Li
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM), the deadliest and most common adult brain malignancy, is molecularly and clinically heterogeneous. The most common subtype (both primary and recurrent), mesenchymal (MES)-GBM, has the worst prognosis and highest treatment resistance. MES-GBM exhibits hyperactive transcriptional coactivator with PDZ-binding motif (TAZ), a Hippo tumor suppressive pathway effector whose expression in GBMs predicts short survival. Yet, how Hippo-TAZ dysregulation might drive GBM MES transition remains elusive, precluding subtype-specific treatments. Tumor evolution requires signaling dysregulation and co-opting the tumor microenvironment (TME). Understanding GBM heterogeneity was recently complicated by the notion that subtypes vary in TME immune composition. The MES-GBM TME is differentially-distorted in silico, with more tumor-associated macrophages/microglia (TAMs) and neutrophils (TANs). Yet, how TAZ hyperactivity, MES transition, and GBM TME distortion interrelate and impact tumor progression remains unknown. We suspected that TME distortion facilitates immune evasion, MES transition, and tumor progression, worsening treatment responses. To test this, we devised an orthotopic xenograft mouse model phenotypically and histopathologically recapitulating human MES-GBM by expressing constitutively-active TAZ (TAZ4SA) in human GBM cells lacking MES signatures (GBM4SA). GBM4SA mice lived significantly shorter compared to mice with GBM expressing vector (GBMvector) or mutant TAZ unable to bind its effector, TEAD (GBM4SA-S51A). Moreover, more myeloid cells infiltrate the GBM4SA TME than the GBMvector or GBM4SA-S51A TMEs. While most myeloid cells infiltrating the GBMvector and GBM4SA-S51A TMEs were TAMs, most infiltrating the GBM4SA TME were TANs, suggesting TAZ hyperactivation differentially distorts the TME. Next, to delineate the roles of TANs in GBM4SA tumor progression, mice were depleted of neutrophils by administering Ly6G antibody. Serial blood smears and flow cytometry revealed effective depletion was achieved. We are currently investigating the impact of systemic neutrophil depletion on GBM mesenchymal transition and tumor progression in hopes of informing future GBM clinical management and novel TME-targeted immunotherapies.
Annual Report October 2000 to September 2001
Authors: A J KNOX
Journal: Thorax (2001)

This has been our busiest year as editors of Thorax , continuing the trend reported last year.1 The number of submissions to the journal has risen again, particularly for original papers (table 1). The geographical distribution of submissions continues to reflect the international flavour of the journal, and for the first time we received more submissions from Western Europe than from the UK (table 2). Our acceptance rate (table 3) and the time …
RNA Nanotechnology-Mediated Cancer Immunotherapy
Authors: Yao-Xin Lin, Yi Wang, Sara Blake, Mian Yu, Lin Mei, Hao Wang, Jinjun Shi
Journal: Theranostics (2019)

RNA molecules (e.g., siRNA, microRNA, and mRNA) have shown tremendous potential for immunomodulation and cancer immunotherapy. They can activate both innate and adaptive immune system responses by silencing or upregulating immune-relevant genes. In addition, mRNA-based vaccines have recently been actively pursued and tested in cancer patients, as a form of treatment. Meanwhile, various nanomaterials have been developed to enhance RNA delivery to the tumor and immune cells. In this review article, we summarize recent advances in the development of RNA-based therapeutics and their applications in cancer immunotherapy. We also highlight the variety of nanoparticle platforms that have been used for RNA delivery to elicit anti-tumor immune responses. Finally, we provide our perspectives of potential challenges and opportunities of RNA-based nanotherapeutics in clinical translation towards cancer immunotherapy.